Literature DB >> 25833100

Pseudocatalytic Antiaggregation Activity of Antibodies: Immunoglobulins can Influence α-Synuclein Aggregation at Substoichiometric Concentrations.

Leonid Breydo1,2, Dave Morgan2,3, Vladimir N Uversky4,5,6,7,8.   

Abstract

Protein aggregation is involved in a variety of diseases. Alteration of the aggregation pathway, either to produce less toxic structures or to increase aggregate clearance, is a promising therapeutic route. Both active and passive immunization has been used for this purpose. However, the mechanism of action of antibodies on protein aggregates is not completely clear especially given poor ability of antibodies to cross blood-brain barrier. Here, we have shown that antibodies can interfere with protein aggregation at substoichiometric concentrations (as low as 1:1000 antibody to protein ratio). This is an indication that antibodies interact with aggregation intermediates in chaperone-like manner altering the aggregation pathways at very low antibody levels. This observation supports earlier suggestions that antibodies can inhibit aggregation by interaction with low abundance aggregation intermediates.

Entities:  

Keywords:  Antibodies; Parkinson’s disease; Protein aggregation; α-Synuclein

Mesh:

Substances:

Year:  2015        PMID: 25833100     DOI: 10.1007/s12035-015-9148-8

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  36 in total

Review 1.  A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders.

Authors:  Vladimir N Uversky
Journal:  J Biomol Struct Dyn       Date:  2003-10

Review 2.  Inhibition of amyloid formation.

Authors:  Torleif Härd; Christofer Lendel
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

3.  Rational design of potent domain antibody inhibitors of amyloid fibril assembly.

Authors:  Ali Reza A Ladiwala; Moumita Bhattacharya; Joseph M Perchiacca; Ping Cao; Daniel P Raleigh; Andisheh Abedini; Ann Marie Schmidt; Jobin Varkey; Ralf Langen; Peter M Tessier
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-15       Impact factor: 11.205

4.  Molecular basis of β-amyloid oligomer recognition with a conformational antibody fragment.

Authors:  Isabel Morgado; Karin Wieligmann; Magdalena Bereza; Raik Rönicke; Katrin Meinhardt; Karthikeyan Annamalai; Monika Baumann; Jessica Wacker; Peter Hortschansky; Miroslav Malešević; Christoph Parthier; Christian Mawrin; Cordelia Schiene-Fischer; Klaus G Reymann; Milton T Stubbs; Jochen Balbach; Matthias Görlach; Uwe Horn; Marcus Fändrich
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-18       Impact factor: 11.205

5.  Influence of conformational antibodies on dissociation of fibrillar amyloid beta (A beta 1-42) in vitro.

Authors:  Sarada Subramanian; Sowmya Madhavadas; Preetha Balasubramanian
Journal:  Indian J Exp Biol       Date:  2009-05       Impact factor: 0.818

Review 6.  Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.

Authors:  Vladimir N Uversky; David Eliezer
Journal:  Curr Protein Pept Sci       Date:  2009-10       Impact factor: 3.272

7.  Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Michael Mante; Leslie Crews; Brian Spencer; Anthony Adame; Christina Patrick; Margarita Trejo; Kiren Ubhi; Troy T Rohn; Sarah Mueller-Steiner; Peter Seubert; Robin Barbour; Lisa McConlogue; Manuel Buttini; Dora Games; Dale Schenk
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

8.  Antibodies against alpha-synuclein reduce oligomerization in living cells.

Authors:  Thomas Näsström; Susana Gonçalves; Charlotte Sahlin; Eva Nordström; Valentina Screpanti Sundquist; Lars Lannfelt; Joakim Bergström; Tiago F Outeiro; Martin Ingelsson
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240

9.  DNAJB6 is a peptide-binding chaperone which can suppress amyloid fibrillation of polyglutamine peptides at substoichiometric molar ratios.

Authors:  Cecilia Månsson; Vaishali Kakkar; Elodie Monsellier; Yannick Sourigues; Johan Härmark; Harm H Kampinga; Ronald Melki; Cecilia Emanuelsson
Journal:  Cell Stress Chaperones       Date:  2013-08-01       Impact factor: 3.667

10.  Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation.

Authors:  Alexander K Buell; Céline Galvagnion; Ricardo Gaspar; Emma Sparr; Michele Vendruscolo; Tuomas P J Knowles; Sara Linse; Christopher M Dobson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-09       Impact factor: 11.205

View more
  5 in total

1.  Bacterial Chaperones CsgE and CsgC Differentially Modulate Human α-Synuclein Amyloid Formation via Transient Contacts.

Authors:  Erik Chorell; Emma Andersson; Margery L Evans; Neha Jain; Anna Götheson; Jörgen Åden; Matthew R Chapman; Fredrik Almqvist; Pernilla Wittung-Stafshede
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

2.  Autoimmune Responses to Soluble Aggregates of Amyloidogenic Proteins Involved in Neurodegenerative Diseases: Overlapping Aggregation Prone and Autoimmunogenic regions.

Authors:  Sandeep Kumar; A Mary Thangakani; R Nagarajan; Satish K Singh; D Velmurugan; M Michael Gromiha
Journal:  Sci Rep       Date:  2016-02-29       Impact factor: 4.379

3.  Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies.

Authors:  Tomasz Brudek; Kristian Winge; Jonas Folke; Søren Christensen; Karina Fog; Bente Pakkenberg; Lars Østergaard Pedersen
Journal:  Mol Neurodegener       Date:  2017-06-07       Impact factor: 14.195

Review 4.  Looking at the recent advances in understanding α-synuclein and its aggregation through the proteoform prism.

Authors:  Vladimir N Uversky
Journal:  F1000Res       Date:  2017-04-20

5.  Editorial: Immunotherapy for Tumor in the Brain: Insights From-and For-Other Tumor Sites.

Authors:  Lois A Lampson
Journal:  Front Oncol       Date:  2018-04-27       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.